Rick Groleau

Rick Groleau from Cantor Fitzgerald inquired about Asceniv's proportion of total sales and its projected contribution to ADMA Biologics' future revenue guidance, specifically regarding product mix and margin expansion. He also asked for an update on the company's efforts to expand third-party supply contracts for RSV plasma.

Answer

President and CEO Adam Grossman and CFO and Treasurer Brad Tade confirmed Asceniv's significant growth, reaching $363 million in net revenue for 2025, representing a 51% year-over-year increase and approximately 70% of total product mix. They anticipate continued mix shift towards Asceniv, with Bivigam remaining flat to down, driving further gross margin expansion, especially with the first full year of yield-enhanced production in 2026. Regarding plasma supply, they reported successful performance of third-party agreements, including a new contract adding access to over 280 plasma collection centers, ensuring long-term high-titer plasma supply visibility.